Genome integrity is protected by the cell-cycle checkpoints that prevent cell proliferation in the presence of DNA damage and allow time for DNA repair. The transient checkpoint arrest together with cellular senescence represent an intrinsic barrier to tumorigenesis. Tumor suppressor p53 is an integral part of the checkpoints and its inactivating mutations promote cancer growth. Protein phosphatase magnesium-dependent 1 (PPM1D) is a negative regulator of p53. Although its loss impairs recovery from the G2 checkpoint and promotes induction of senescence, amplification of the PPM1D locus or gain-of-function truncating mutations of PPM1D occur in various cancers. Here we used a transgenic mouse model carrying a truncating mutation in exon 6 of PPM1D (Ppm1dT). As with human cell lines, we found that the truncated PPM1D was present at high levels in the mouse thymus. Truncated PPM1D did not affect differentiation of T-cells in the thymus but it impaired their response to ionizing radiation (IR). Thymocytes in Ppm1dT/+ mice did not arrest in the checkpoint and continued to proliferate despite the presence of DNA damage. In addition, we observed a decreased level of apoptosis in the thymi of Ppm1dT/+ mice. Moreover, the frequency of the IR-induced T-cell lymphomas increased in Ppm1dT/+Trp53+/- mice resulting in decreased survival. We conclude that truncated PPM1D partially suppresses the p53 pathway in the mouse thymus and potentiates tumor formation under the condition of a partial loss of p53 function.

Department of Developmental and Cell Biology Faculty of Science Charles University Albertov 6 CZ12800 Prague Czech Republic

Laboratory of Cancer Cell Biology Institute of Molecular Genetics of the Czech Academy of Sciences Videnska 1083 CZ14220 Prague Czech Republic

Zobrazit více v PubMed

Bartek J., Lukas J. DNA damage checkpoints: From initiation to recovery or adaptation. Curr. Opin. Cell Biol. 2007;19:238–245. doi: 10.1016/j.ceb.2007.02.009. PubMed DOI

Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–429. doi: 10.1016/S1535-6108(03)00110-7. PubMed DOI

Medema R.H., Macůrek L. Checkpoint control and cancer. Oncogene. 2012;31:2601–2613. doi: 10.1038/onc.2011.451. PubMed DOI

Soto M., Raaijmakers J.A., Bakker B., Spierings D.C.J., Lansdorp P.M., Foijer F., Medema R.H. p53 Prohibits Propagation of Chromosome Segregation Errors that Produce Structural Aneuploidies. Cell Rep. 2017;19:2423–2431. doi: 10.1016/j.celrep.2017.05.055. PubMed DOI

Shieh S.-Y., Ikeda M., Taya Y., Prives C. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2. Cell. 1997;91:325–334. doi: 10.1016/S0092-8674(00)80416-X. PubMed DOI

Shieh S., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000;14:289–300. PubMed PMC

el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–825. doi: 10.1016/0092-8674(93)90500-P. PubMed DOI

Sørensen C.S., Syljuåsen R.G., Falck J., Schroeder T., Rönnstrand L., Khanna K.K., Zhou B.B., Bartek J., Lukas J. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell. 2003;3:247–258. doi: 10.1016/S1535-6108(03)00048-5. PubMed DOI

Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to Sustain G2 Arrest after DNA Damage. Science. 1998;282:1497–1501. doi: 10.1126/science.282.5393.1497. PubMed DOI

Lindqvist A., de Bruijn M., Macurek L., Bras A., Mensinga A., Bruinsma W. Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression. EMBO J. 2009;28:3196–3206. doi: 10.1038/emboj.2009.246. PubMed DOI PMC

Jaiswal H., Benada J., Müllers E., Akopyan K., Burdova K., Koolmeister T., Helleday T., Medema R.H., Macurek L., Lindqvist A. ATM/Wip1 activities at chromatin control Plk1 re-activation to determine G2 checkpoint duration. EMBO J. 2017;36:2161–2176. doi: 10.15252/embj.201696082. PubMed DOI PMC

Shreeram S., Demidov O.N., Hee W.K., Yamaguchi H., Onishi N., Kek C., Timofeev O.N., Dudgeon C., Fornace A.J., Anderson C.W., et al. Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways. Mol. Cell. 2006;23:757–764. doi: 10.1016/j.molcel.2006.07.010. PubMed DOI

Fiscella M., Zhang H., Fan S., Sakaguchi K., Shen S., Mercer W.E., Vande Woude G.F., O’Connor P.M., Appella E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl. Acad. Sci. USA. 1997;94:6048–6053. doi: 10.1073/pnas.94.12.6048. PubMed DOI PMC

Krenning L., Feringa F.M., Shaltiel I.A., van den Berg J., Medema R.H. Transient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence. Mol. Cell. 2014;55:59–72. doi: 10.1016/j.molcel.2014.05.007. PubMed DOI

Müllers E., Cascales H.S., Jaiswal H., Saurin A.T., Lindqvist A. Nuclear translocation of Cyclin B1 marks the restriction point for terminal cell cycle exit in G2 phase. Cell Cycle. 2014;13:2733–2743. doi: 10.4161/15384101.2015.945831. PubMed DOI PMC

Feringa F.M., Raaijmakers J.A., Hadders M.A., Vaarting C., Macurek L., Heitink L., Krenning L., Medema R.H. Persistent repair intermediates induce senescence. Nat. Commun. 2018;9:1–10. doi: 10.1038/s41467-018-06308-9. PubMed DOI PMC

Burdova K., Storchova R., Palek M., Macurek L. WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors. Cells. 2019;8:1258. doi: 10.3390/cells8101258. PubMed DOI PMC

Purvis J.E., Karhohs K.W., Mock C., Batchelor E., Loewer A., Lahav G. p53 dynamics control cell fate. Science. 2012;336:1440–1444. doi: 10.1126/science.1218351. PubMed DOI PMC

Barr A.R., Cooper S., Heldt F.S., Butera F., Stoy H., Mansfeld J., Novák B., Bakal C. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat. Commun. 2017;8:1–17. doi: 10.1038/ncomms14728. PubMed DOI PMC

Shaltiel I.A., Aprelia M., Saurin A.T., Chowdhury D., Kops G.J.P.L., Voest E.E., Medema R.H. Distinct phosphatases antagonize the p53 response in different phases of the cell cycle. Proc. Natl. Acad. Sci. USA. 2014;111:7313–7318. doi: 10.1073/pnas.1322021111. PubMed DOI PMC

Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–870. doi: 10.1038/nature03482. PubMed DOI

Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.-V.F., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633–637. doi: 10.1038/nature05268. PubMed DOI

Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444:638–642. doi: 10.1038/nature05327. PubMed DOI

Bulavin D.V., Demidov O.N., Saito S.I., Kauraniemi P., Phillips C., Amundson S.A., Ambrosino C., Sauter G., Nebreda A.R., Anderson C.W., et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 2002;31:210–215. doi: 10.1038/ng894. PubMed DOI

Emelyanov A., Bulavin D.V. Wip1 phosphatase in breast cancer. Oncogene. 2015;34:4429–4438. doi: 10.1038/onc.2014.375. PubMed DOI

Yu E., Ahn Y.S., Jang S.J., Kim M.J., Yoon H.S., Gong G., Choi J. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res. Treat. 2007;101:269–278. doi: 10.1007/s10549-006-9304-y. PubMed DOI

Bulavin D.V., Phillips C., Nannenga B., Timofeev O., Donehower L.A., Anderson C.W., Appella E., Fornace A.J. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19Arf pathway. Nat. Genet. 2004;36:343–350. doi: 10.1038/ng1317. PubMed DOI

Demidov O.N., Kek C., Shreeram S., Timofeev O., Fornace A.J., Appella E., Bulavin D.V. The role of the MKK6//p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene. 2006;26:2502–2506. doi: 10.1038/sj.onc.1210032. PubMed DOI

Pechackova S., Burdova K., Benada J., Kleiblova P., Jenikova G., Macurek L. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3. Oncotarget. 2016;7:14458–14475. doi: 10.18632/oncotarget.7363. PubMed DOI PMC

Pecháčková S., Burdová K., Macurek L. WIP1 phosphatase as pharmacological target in cancer therapy. J. Mol. Med. 2017;95:589–599. doi: 10.1007/s00109-017-1536-2. PubMed DOI PMC

Kleiblova P., Shaltiel I.A., Benada J., Sevčík J., Pecháčková S., Pohlreich P., Voest E.E., Dundr P., Bartek J., Kleibl Z., et al. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J. Cell Biol. 2013;201:511–521. doi: 10.1083/jcb.201210031. PubMed DOI PMC

Zhang L., Chen L.H., Wan H., Yang R., Wang Z., Feng J., Yang S., Jones S., Wang S., Zhou W., et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat. Genet. 2014;46:726–730. doi: 10.1038/ng.2995. PubMed DOI PMC

Ruark E., Snape K., Humburg P., Loveday C., Bajrami I., Brough R., Rodrigues D.N., Renwick A., Seal S., Ramsay E., et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493:406–410. doi: 10.1038/nature11725. PubMed DOI PMC

Kahn J.D., Miller P.G., Silver A.J., Sellar R.S., Bhatt S., Gibson C., McConkey M., Adams D., Mar B., Mertins P., et al. PPM1D truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018;132:1095–1105. doi: 10.1182/blood-2018-05-850339. PubMed DOI PMC

Burocziova M., Burdova K., Martinikova A.S., Kasparek P., Kleiblova P., Danielsen S.A., Borecka M., Jenikova G., Janečková L., Pavel J., et al. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Cell Death Dis. 2019;10:1–15. doi: 10.1038/s41419-019-2057-4. PubMed DOI PMC

Germain R.N. T-cell development and the CD4–CD8 lineage decision. Nat. Rev. Immunol. 2002;2:309–322. doi: 10.1038/nri798. PubMed DOI

Ceredig R., Rolink T. A positive look at double-negative thymocytes. Nat. Rev. Immunol. 2002;2:888–897. doi: 10.1038/nri937. PubMed DOI

Bogue M.A., Zhu C., Aguilar-Cordova E., Donehower L.A., Roth D.B. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in scid mouse thymocytes. Genes Dev. 1996;10:553–565. doi: 10.1101/gad.10.5.553. PubMed DOI

Guidos C.J., Williams C.J., Grandal I., Knowles G., Huang M.T., Danska J.S. V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. 1996;10:2038–2054. doi: 10.1101/gad.10.16.2038. PubMed DOI

Jiang D., Lenardo M.J., Zúñiga-Pflücker J.C. p53 prevents maturation to the CD4+CD8+ stage of thymocyte differentiation in the absence of T cell receptor rearrangement. J. Exp. Med. 1996;183:1923–1928. doi: 10.1084/jem.183.4.1923. PubMed DOI PMC

Schito M., Demidov O., Saito S., Ashwell J., Appella E. Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation. J. Immunol. 2006;176:4818–4825. doi: 10.4049/jimmunol.176.8.4818. PubMed DOI

Sun L., Li H., Luo H., Zhang L., Hu X., Yang T., Sun C., Chen H., Zhang L., Zhao Y. Phosphatase Wip1 is essential for the maturation and homeostasis of medullary thymic epithelial cells in mice. J. Immunol. 2013;191:3210–3220. doi: 10.4049/jimmunol.1300363. PubMed DOI

Yi W., Hu X., Chen Z., Liu L., Tian Y., Chen H., Cong Y.S., Yang F., Zhang L., Rudolph K.L., et al. Phosphatase Wip1 controls antigen-independent B-cell development in a p53-dependent manner. Blood. 2015;126:620–628. doi: 10.1182/blood-2015-02-624114. PubMed DOI PMC

Uyanik B., Grigorash B.B., Goloudina A.R., Demidov O.N. DNA damage-induced phosphatase Wip1 in regulation of hematopoiesis, immune system and inflammation. Cell Death Discov. 2017;3:1–5. doi: 10.1038/cddiscovery.2017.18. PubMed DOI PMC

Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994;4:1–7. doi: 10.1016/S0960-9822(00)00002-6. PubMed DOI

Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 2012;9:676–682. doi: 10.1038/nmeth.2019. PubMed DOI PMC

Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43–50. doi: 10.1038/34112. PubMed DOI

Gorczyca W., Bruno S., Darzynkiewicz R., Gong J., Darzynkiewicz Z. DNA strand breaks occurring during apoptosis—Their early insitu detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int. J. Oncol. 1992;1:639–648. doi: 10.3892/ijo.1.6.639. PubMed DOI

Zhao R., Kaakati R., Lee A.K., Liu X., Li F., Li C.Y. Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond. Cancer Metastasis Rev. 2018;37:227–236. doi: 10.1007/s10555-018-9736-y. PubMed DOI PMC

Tang H.L., Tang H.M., Mak K.H., Hu S., Wang S.S., Wong K.M., Wong C.S., Wu H.Y., Law H.T., Liu K., et al. Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol. Biol. Cell. 2012;23:2240–2252. doi: 10.1091/mbc.e11-11-0926. PubMed DOI PMC

Kemp C.J., Wheldon T., Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 1994;8:66–69. doi: 10.1038/ng0994-66. PubMed DOI

Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–221. doi: 10.1038/356215a0. PubMed DOI

Ströbel P., Hartmann E., Rosenwald A., Kalla J., Ott G., Friedel G., Schalke B., Kasahara M., Tomaru U., Marx A. Corticomedullary differentiation and maturational arrest in thymomas. Histopathology. 2014;64:557–566. doi: 10.1111/his.12279. PubMed DOI

Odaka C., Loranger A., Takizawa K., Ouellet M., Tremblay M.J., Murata S., Inoko A., Inagaki M., Marceau N. Keratin 8 is required for the maintenance of architectural structure in thymus epithelium. PLoS ONE. 2013;8:e75101. doi: 10.1371/journal.pone.0075101. PubMed DOI PMC

Lauder A.J., Jolin H.E., Smith P., van den Berg J.G., Jones A., Wisden W., Smith K.G., Dasvarma A., Fallon P.G., McKenzie A.N. Lymphomagenesis, hydronephrosis, and autoantibodies result from dysregulation of IL-9 and are differentially dependent on Th2 cytokines. J. Immunol. 2004;173:113–122. doi: 10.4049/jimmunol.173.1.113. PubMed DOI

Hsu J.I., Dayaram T., Tovy A., De Braekeleer E., Jeong M., Wang F., Zhang J., Heffernan T.P., Gera S., Kovacs J.J., et al. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018;23:700–713. doi: 10.1016/j.stem.2018.10.004. PubMed DOI PMC

Rauta J., Alarmo E.-L., Kauraniemi P., Karhu R., Kuukasjärvi T., Kallioniemi A. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res. Treat. 2006;95:257–263. doi: 10.1007/s10549-005-9017-7. PubMed DOI

PPM1D activity promotes the replication stress caused by cyclin E1 overexpression

Ppm1d truncating mutations promote the development of genotoxic stress-induced AML